Clinical Trial VICCHEM1073
The Role of the Native Immune System in Determining Outcome Following AML Induction Therapy
- Protocol No. VICCHEM1073
- Open Date: 08/19/2011
- Staging: Pilot
- Age Group: Adults
- Scope: Local
- Objective: A descriptive study of cellular immunity in previously untreated AML patients
- Disease Sites: Leukemia
- Therapies: Correlative
- Drugs: None Specified
- Participating Institutions: Vanderbilt University
- Secondary Protocol No: Not Specified
Patients diagnosed with acute myeloid leukemia (AML) and are about to begin treatment are being asked to participate in this study. This study does not involve any kind of experimental treatment or procedures. In this study we will follow the natural course of AML while participants are getting treatment. That treatment can be either routine care (also called standard of care) or as part of a clinical research study that the participant has already agreed to take part in. The only procedures that will be done for this study will be to collect blood samples and bone marrow samples. These samples will be stored for research purposes.
Not provided. Please call for more information.